Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-label Dose Escalation Study of AT13387 in Patients With Metastatic Solid Tumors

NCT00878423 is registered in ClinicalTrials.gov with Astex Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00878423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00878423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-label Dose Escalation Study of AT13387 in Patients With Metastatic Solid Tumors
Lead sponsor
Astex Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2008
Completion date
March 31, 2014
Enrollment
62 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic solid tumors